Direct cellular delivery of human proteasomes to delay tau aggregation.
about
Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative DiseasesTau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors.Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity.Isolation and Characterization of RNA Aptamers against a Proteasome-Associated Deubiquitylating Enzyme UCH37.Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradationDocosahexaenoic acid-mediated protein aggregates may reduce proteasome activity and delay myotube degradation during muscle atrophy in vitro.Nanotechnology for protein delivery: Overview and perspectives.Improving drug delivery technology for treating neurodegenerative diseases.The Proteasome and Oxidative Stress in Alzheimer's Disease.Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.Intracellular chromobody delivery by mesoporous silica nanoparticles for antigen targeting and visualization in real time.The arginylation branch of the N-end rule pathway positively regulates cellular autophagic flux and clearance of proteotoxic proteins.Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease.Image-Based Analysis of Intracellular Tau Aggregation by Using Tau-BiFC Cell Model.Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.Orderly nucleic acid aggregates by electrostatic self-assembly in single cells for miRNA detection and visualizing.Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology.Lipid-Coated Mesoporous Silica Nanoparticles for the Delivery of the ML336 Antiviral to Inhibit Encephalitic Alphavirus Infection
P2860
Q28073686-10DEB20A-9EE4-418F-88D1-67B6A54C94B3Q33559307-F3D0682F-1524-4DB3-A0DF-20D55B9A6D2AQ34492739-F78A50D4-53CD-42D5-A1C7-94CDDE7945EDQ34506149-EA76888C-F62F-49CE-AF38-FE0792B47477Q35682065-21A1ABB1-F080-4E16-879C-BFE62795B44BQ36216365-47793BD0-0473-46C4-9C0F-9898BEAA325CQ36675188-197408A0-A6F8-4478-9227-80930127DC8DQ37624469-8B408985-D526-405E-974E-A47171A37BA4Q38605185-0EFD8EA4-C542-4ABC-81D3-FD225BBC24D6Q38769989-DCB55CDF-AA42-435F-878C-D7EB6A34E7C8Q38843876-9CA161A3-1E6D-4675-B7DC-0C2F65B83402Q38983187-F0835DFB-4F10-4951-9313-5A34FD51018BQ41508323-8AE7153C-FBD9-4BDE-AA38-DC6041DB8D01Q41889716-6389A4C9-7B74-49CB-B331-C6C99F7DAE58Q47724056-DB46F986-71FB-4D5B-ADB4-5CF8E0224301Q48395284-C21C8CE5-6CA0-4697-B9C9-CF5C406D10C5Q50632272-0D2882B6-B1DB-46F0-B084-7B82A3A8F4F6Q50862678-7DB379DF-9612-456B-8E41-624A73AC004CQ55003043-DBE7507D-3F0C-458E-8BF9-A4865E789779Q58726168-76C5B189-1BCF-496B-8A68-E1034B1D9449
P2860
Direct cellular delivery of human proteasomes to delay tau aggregation.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Direct cellular delivery of human proteasomes to delay tau aggregation.
@en
type
label
Direct cellular delivery of human proteasomes to delay tau aggregation.
@en
prefLabel
Direct cellular delivery of human proteasomes to delay tau aggregation.
@en
P2093
P2860
P356
P1476
Direct cellular delivery of human proteasomes to delay tau aggregation.
@en
P2093
Cheolhee Won
Dal-Hee Min
Dong Hoon Han
Hee-Kyung Na
Jeff Kuret
Jung Hoon Lee
Kwang Pyo Kim
Min Jae Lee
Seung-Han Lee
Won Hoon Choi
P2860
P2888
P356
10.1038/NCOMMS6633
P407
P577
2014-12-05T00:00:00Z
P5875
P6179
1044385133